Navigation Links
BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
Date:5/10/2013

Madison WI (PRWEB) May 10, 2013

Join us for a webinar on May 15, 2013 at 12:00 PM EDT.

An Integrated instrument-Reagent Platform for Screening and Profiling Kinases and Methyltransferases

Register now! https://attendee.gotowebinar.com/register/5177117919789326592

Biochemical HTS assays are a critical component of drug discovery programs focused on enzyme targets like kinases and methyltransferases. Assembling high quality assay reagents and validating them on a detection platform that can deliver speed, accuracy and reproducibility can consume a significant amount of time and resources. The shift toward screening focused libraries against multiple targets in parallel can add to the assay development burden substantially.

In this webinar, you will learn:

  • How Transcreener HTS Assays allow robust, initial velocity detection of any kinase or methyltransferase enzyme.
  • How to sync Transcreener assays with BMG’s Pherastar Plus plate reader to generate high quality screening or profiling data.
  • How to use Pherastar’s onboard software to determine IC50 values directly from raw assay data without constructing a standard curve.
  • How to eliminate costly biochemical assay development using turnkey kits combining Transcreener assays and pre-calibrated kinase and methyltransferase enzymes and substrates.

Participants should come away confident that they can apply a robust, cost-effective, user friendly solution to immediately begin screening/profiling multiple kinases or methyltransferases in parallel.

After registering, you will receive a confirmation email containing information about joining the webinar.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

About BMG LABTECH. BMG LABTECH is ‘The Microplate Company’. Since we are committed to producing microplate readers you can be assured that we will provide you with the best detection that German engineering can provide. The PHERAstar line of microplate readers are our top of the line multi-functional readers for high-throughput screening; providing you with high sensitivity and fast read-times in all detection modes. The PHERAstar employs assay specific optic modules that have been optimized to perform well whether your test detects fluorescence intensity, fluorescence polarization, time-resolved FRET or many other detection modes.

For more information about the variety of microplate readers that BMG LABTECH offers, please visit our website: http://www.bmglabtech.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10714515.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
2. Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures
3. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
4. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
5. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
6. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
7. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
8. iBio, Inc. Prices $10 Million Public Offering
9. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
10. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Spherix Announces Registered Direct Offering of $1.15 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):